BR0111440A - Compostos eficazes como agonistas do (beta)2-adrenorreceptor bem como inibidores de pde4 - Google Patents

Compostos eficazes como agonistas do (beta)2-adrenorreceptor bem como inibidores de pde4

Info

Publication number
BR0111440A
BR0111440A BR0111440-9A BR0111440A BR0111440A BR 0111440 A BR0111440 A BR 0111440A BR 0111440 A BR0111440 A BR 0111440A BR 0111440 A BR0111440 A BR 0111440A
Authority
BR
Brazil
Prior art keywords
well
beta
pde4 inhibitors
compounds effective
adrenoreceptor agonists
Prior art date
Application number
BR0111440-9A
Other languages
English (en)
Inventor
Armin Hatzelmann
Daniela Bundschuh
Manfrid Eltze
Yvone Van Der Laan
Hendrik Timmermann
Johannes Christiaans
Paulus Brundel
Original Assignee
Altana Pharma Ag
Altana Pharma B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altana Pharma Ag, Altana Pharma B V filed Critical Altana Pharma Ag
Publication of BR0111440A publication Critical patent/BR0111440A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"COMPOSTOS EFICAZES COMO AGONISTAS DO <225>2-ADRENORRECEPTOR BEM COMO INIBIDORES DE PDE4". A invenção refere-se a compostos da fórmula I nos quais Ar~ 1~, A, R6, R7, R8 e Ar~ 2~ têm os significados conforme fornecidos na descrição que são novos terapêuticos brónquicos eficazes.
BR0111440-9A 2000-06-05 2001-06-01 Compostos eficazes como agonistas do (beta)2-adrenorreceptor bem como inibidores de pde4 BR0111440A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00111795 2000-06-05
PCT/EP2001/006230 WO2001094319A1 (en) 2000-06-05 2001-06-01 Compounds effective as beta-2-adrenoreceptor agonists as well as pde4-inhibitors

Publications (1)

Publication Number Publication Date
BR0111440A true BR0111440A (pt) 2003-06-03

Family

ID=8168897

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0111440-9A BR0111440A (pt) 2000-06-05 2001-06-01 Compostos eficazes como agonistas do (beta)2-adrenorreceptor bem como inibidores de pde4

Country Status (20)

Country Link
US (1) US6933296B2 (pt)
EP (1) EP1296956A1 (pt)
JP (1) JP2003535850A (pt)
KR (1) KR20030031907A (pt)
CN (1) CN1471515A (pt)
AU (2) AU2001262332B2 (pt)
BR (1) BR0111440A (pt)
CA (1) CA2411351A1 (pt)
CZ (1) CZ20023997A3 (pt)
EA (1) EA005824B1 (pt)
HK (1) HK1052346A1 (pt)
HU (1) HUP0301240A3 (pt)
IL (1) IL152846A0 (pt)
MX (1) MXPA02012042A (pt)
NO (1) NO20025811L (pt)
NZ (1) NZ522882A (pt)
PL (1) PL358057A1 (pt)
SK (1) SK17052002A3 (pt)
WO (1) WO2001094319A1 (pt)
ZA (1) ZA200209598B (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030074817A (ko) 2001-02-15 2003-09-19 알타나 파마 아게 Ｐｄｅ4 억제제로서의 프탈라지논-피페리디노-유도체
NZ529221A (en) 2001-04-25 2005-04-29 Altana Pharma Ag Phthalazinones with PDE-inhibiting properties for treatment of airway disorders and other inflammatory conditions
KR20030089723A (ko) 2001-04-25 2003-11-22 알타나 파마 아게 피페라지노-유도체 및 이것의 ｐｄｅ4 억제제로서의 용도
ES2195785B1 (es) * 2002-05-16 2005-03-16 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
EP1537100B1 (en) * 2002-08-10 2007-04-25 ALTANA Pharma AG Pyrrolidinedione substituted piperidine-phthalazones as pde4 inhibitors
PL373146A1 (en) * 2002-08-10 2005-08-22 Altana Pharma Ag Pyridazinone-derivatives as pde4 inhibitors
EP1542987A1 (en) * 2002-08-10 2005-06-22 ALTANA Pharma AG Piperidine-n-oxide-derivatives
US20070117978A1 (en) * 2002-12-23 2007-05-24 Artesian Therapecutics, Inc Cardiotonic compounds with inhibitory activity against beta-adrenergic receptors and phosphodiesterase
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
ES2232306B1 (es) 2003-11-10 2006-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
JP4778449B2 (ja) 2004-02-04 2011-09-21 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｐｄｅ４インヒビターとしての２−（ピペリジン−４−イル）−４，５−ジヒドロ−２ｈ−ピリダジン−３−オン誘導体
EP1716123A1 (en) * 2004-02-04 2006-11-02 Altana Pharma AG Pyridazinone derivatives and their use as pde4 inhibitors
ES2251866B1 (es) 2004-06-18 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
EP2218442A1 (en) 2005-11-09 2010-08-18 CombinatoRx, Inc. Methods, compositions, and kits for the treatment of ophthalmic disorders
GB0602778D0 (en) 2006-02-10 2006-03-22 Glaxo Group Ltd Novel compound
GB0805535D0 (en) 2008-03-27 2008-04-30 Univ Leicester Scar prevention
US8969348B2 (en) 2008-08-13 2015-03-03 Boehringer Ingelheim International Gmbh Chymase inhibitors
NZ603136A (en) * 2010-05-10 2014-11-28 Gilead Sciences Inc Bifunctional quinoline derivatives
AR081377A1 (es) 2010-05-10 2012-08-29 Gilead Sciences Inc Compuestos de pirazolopiridina bifuncionales
BR112013031791A2 (pt) * 2011-06-17 2017-01-31 Takeda Gmbh derivados de ftalazinona-pirrolopirimidinacarboxamida
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
GB2513297A (en) 2013-03-08 2014-10-29 Univ Leicester Methods
AU2019374812A1 (en) 2018-11-06 2021-06-10 Edgewise Therapeutics, Inc. Pyridazinone compounds and uses thereof
EP3877376B1 (en) 2018-11-06 2023-08-23 Edgewise Therapeutics, Inc. Pyridazinone compounds and uses thereof
WO2021231572A1 (en) * 2020-05-13 2021-11-18 Edgewise Therapeutics, Inc. Pyridazinone compounds for the treatment of neuromuscular diseases

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3063196D1 (en) 1979-12-05 1983-06-16 Morishita Pharma Derivatives of 2-substituted-6-phenyl-3(2h)pyridazinone, their production and pharmaceutical compositions containing them
JPS58146571A (ja) 1982-02-25 1983-09-01 Morishita Seiyaku Kk ウレア誘導体およびその製造法
PL164079B1 (pl) * 1990-06-15 1994-06-30 Akad Medyczna posób wytwarzania nowych 2-amlnoalkilopochodnych 5-aminometyleno-6-/p-chlorofenylo /-4,5-dihydro-2H- plrydazyn -3-onu
JP3100984B2 (ja) 1992-12-02 2000-10-23 ファイザー・インク． 選択的ｐｄｅ▲下ｉ▼▲下ｖ▼阻害物質としてのカテコールジエーテル類
DE19533975A1 (de) * 1995-09-14 1997-03-20 Merck Patent Gmbh Arylalkyl-diazinone
PT971901E (pt) * 1997-01-15 2003-07-31 Altana Pharma Ag Ftalazinonas
JP2001513097A (ja) 1997-02-28 2001-08-28 ビイク グルデン ロンベルク ヒエーミツシエ フアブリーク ゲゼルシヤフト ミツト ベシユレンクテル ハフツング Ｐｄｅ−抑制物質とアデニル酸シクラーゼ・アゴニストもしくはグアニル酸シクラーゼ・アゴニストとからなる相乗的組み合わせ組成物
US6380196B1 (en) 1997-12-15 2002-04-30 Byk Gulden Lomberg Chemische Fabrik Gmbh Dihydrobenzofurans
AU1760399A (en) * 1997-12-15 1999-07-05 Byk Gulden Lomberg Chemische Fabrik Gmbh New phthalazinones
EP0934933A1 (en) 1998-02-06 1999-08-11 Byk Gulden Lomberg Chemische Fabrik GmbH Phthalazinones
MY126544A (en) 1998-08-26 2006-10-31 Smithkline Beecham Corp Therapies for treating pulmonary diseases

Also Published As

Publication number Publication date
AU6233201A (en) 2001-12-17
MXPA02012042A (es) 2004-08-19
AU2001262332B2 (en) 2006-05-25
CN1471515A (zh) 2004-01-28
JP2003535850A (ja) 2003-12-02
EA005824B1 (ru) 2005-06-30
HUP0301240A3 (en) 2004-03-29
HUP0301240A2 (hu) 2003-12-29
WO2001094319A1 (en) 2001-12-13
CA2411351A1 (en) 2001-12-13
NO20025811D0 (no) 2002-12-03
EP1296956A1 (en) 2003-04-02
KR20030031907A (ko) 2003-04-23
NO20025811L (no) 2003-02-04
PL358057A1 (en) 2004-08-09
SK17052002A3 (sk) 2003-12-02
US6933296B2 (en) 2005-08-23
CZ20023997A3 (cs) 2003-05-14
ZA200209598B (en) 2003-07-29
HK1052346A1 (zh) 2003-09-11
US20030195215A1 (en) 2003-10-16
IL152846A0 (en) 2003-06-24
EA200201252A1 (ru) 2003-06-26
NZ522882A (en) 2004-07-30

Similar Documents

Publication Publication Date Title
BR0111440A (pt) Compostos eficazes como agonistas do (beta)2-adrenorreceptor bem como inibidores de pde4
BR9713338A (pt) Benzonaftiridinas como terapêuticos brÈnquicos.
BR0208192A (pt) Derivados espirotricìclicos e seu uso como inibidores da fosfodiesterase-7.
BR9913745A (pt) Cetonas de piridina úteis como herbicidas
BR9811730A (pt) Derivados de n-aroilfenilalanina
BR0109188A (pt) Diarilaminas 5-amida substituìdas como inibidores de mex
BR9908757A (pt) Derivados de 3-hidróxi-4-aril-5-oxopirazolina herbicidamente ativos
BRPI0606379A2 (pt) triazolftalazinas
BR0111206A (pt) Derivados de arilmetilamina para uso como inibidores de triptase
BR9811988A (pt) Derivados de n-alcanoilfenilalanina
YU64701A (sh) Jedinjenja upotrebljiva kao anti-inflamatorna sredstva
BR0308967A (pt) Derivados de quinolina e isoquinolina, um processo para a sua preparação e sua aplicação como inibidores de inflamação
BR0111981A (pt) herbicidas de piridina substituìda
DK1017692T3 (da) 4-Heteroaryl-tetrahydroquinoliner og deres anvendelse som inhibitorer af cholesterolester-transferproteiner
BR0200782A (pt) Compostos para o tratamento da isquemia
BR0309556A (pt) Inibidores de metaloproteinase pirimidina-2,4,6-triona
BR0109317A (pt) Composições contendo componentes agonistas alfa-2-adrenérgicos
BR0010716A (pt) Compostos de fenila substituìdos com atividade imunossupressora e composições farmacêuticas
BRPI0412130A (pt) compostos tetracìclicos como inibidores de c-met
UY25712A1 (es) Benzamidas sustituidas y su aplicación en medicamentos
BRPI0411092A (pt) benzo[b]tiofenos substituìdos com 3-arilsulfanila e com 3-heteroarilsulfanila como agentes terapêuticos
BRPI0511323A (pt) tetraidroisoquinolinas substituìdas usadas na forma de inibidores de mmp, método para a produção e uso das mesmas na forma de drágeas
ATE476419T1 (de) Isochinolinon-kaliumkanalinhibitoren
YU60101A (sh) Derivati rezorcinola
EA200100517A1 (ru) Антагонисты 5ht1 для антидепрессантной терапии

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A,7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2016 DE 25/08/2009.